CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 3

NOW THEREFORE, in consideration of the mutual promises contained in the Agreement and for other good and valuable consideration the receipt and adequacy of which each of the parties does hereby acknowledge, the parties hereby agree to the terms of this Amendment No. 3 as follows:

1. Radius Monitoring of United States study sites in period 2 of the BA058-05-005 study:

(a)  At Radius’s request, Radius will perform monitoring of US study sites in the period from the 6 month visit until the 24 month visit in a Period 2 extension of the clinical study entitled: BA058-05-005 “An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003”. The purpose of this Amendment No. 3 is to introduce monitoring of US sites by Radius. The Clinical Monitoring Plan version 4 dated 08July2015 documents the change in monitoring responsibilities.

2.  Ratification.  Except to the extent expressly amended by this Amendment No. 3, all of the terms, provisions and conditions of the Agreement are hereby ratified and confirmed and shall remain in full force and effect.

3.  General.  This Amendment No. 3 may be executed in counterparts, each of which will be deemed an original with all such counterparts together constituting one instrument.

IN WITNESS WHEREOF the parties have caused this Amendment No. 3 to be executed by their respective duly authorized officers, and have duly delivered and executed this Amendment No. 3 under seal as of the Amendment Date.

1